The scientist jailed for creating gene-edited babies has resurfaced with a brain-computer interface research operation in China, raising sharp questions about scientific ethics, regulatory appetite, and who is willing to fund frontier biotech with a controversial face attached to it.
He Jiankui spent three years in a Chinese prison after shocking the global scientific community in 2018 by announcing the birth of twin girls whose embryos he had edited using CRISPR technology. The conviction was swift, the condemnation universal, and most observers assumed his research career was finished. They were wrong. According to a report from Reuters, He has rebuilt a laboratory in China with a focus on brain-computer interface technology, positioning himself inside one of the most aggressively funded and geopolitically charged fields in science today.
The timing is not accidental. BCI has moved from the fringes of neuroscience into the center of a serious technology competition. Elon Musk's Neuralink implanted its first human patient in January 2024 and has been expanding its trials since. Synchron, backed by Jeff Bezos and Bill Gates among others, has been quietly building a clinical track record with its less invasive stentrode device. And China, which identified BCI as a strategic frontier in its national science planning, has been funding domestic programs at institutions including Zhejiang University and Tianjin University with intent that goes well beyond academic curiosity. For a scientist looking to re-enter the arena, there are few fields with more momentum or more money moving through them right now.
What makes He's return significant is not just the personal story. It is what it reveals about China's calculus when frontier technology and scientific reputation come into conflict. The gene-editing episode was an embarrassment for Chinese science on the world stage, and Beijing was explicit about it. He was prosecuted, not shielded. But prosecution is not the same as permanent exclusion, and allowing a researcher with genuine technical skills to continue working, in a monitored context or otherwise, fits a pattern of prioritizing capability over optics when the strategic stakes are high enough.
BCI sits at precisely that intersection. A successful brain-computer interface program with Chinese characteristics, to borrow the idiom, would have implications for medicine, for military human-machine integration, and for the broader narrative of technological self-sufficiency that Beijing has been constructing since the trade and chip restrictions began tightening. Whether He's specific lab has state backing, private investment, or some combination is a detail that matters enormously for anyone trying to assess how serious this effort is. Reuters' reporting suggests the operation exists, but the funding structure and institutional affiliations remain opaque, which is itself a notable data point.
From an investor's perspective, the reappearance of a figure like He in a high-profile emerging field does something uncomfortable to the due diligence process. BCI is already a sector where hype routinely outpaces clinical evidence. Neuralink generates extraordinary press coverage relative to its current patient numbers. Dozens of startups are raising capital on the promise of non-invasive neural interfaces that have yet to demonstrate anything close to the performance of invasive systems. Layering a scientist with a criminal conviction for exactly the kind of ethics violation that regulators everywhere are most anxious about does not simplify the picture. It complicates it in ways that matter for anyone writing a check or sitting on an institutional review board.
The ethics question does not go away
The deeper issue is not whether He Jiankui is technically competent. By most accounts he is. The issue is what his rehabilitation signals about the frameworks that are supposed to govern research at the edge of what is biologically possible. Gene editing and neural interfaces are not the same technology, but they share a common characteristic: the potential for irreversible consequences in human subjects, and a history of researchers moving faster than consent protocols, regulatory structures, or public understanding could keep up with.
Chinese regulators have been working to tighten oversight of both fields since the CRISPR scandal broke. New rules covering human genetic research were strengthened, and there has been real institutional effort to demonstrate that what He did was an aberration rather than a symptom. Allowing him back into active research, even in a different domain, creates a tension with that narrative that will not be lost on the international scientific community watching from Geneva, Brussels, and Washington.
For readers tracking the intersection of AI, biotech, and national technology competition, the practical question is what this episode reveals about where the guardrails actually are versus where they are said to be. The honest answer is that in any country, including democratic ones, the guardrails tend to flex when the technology is sufficiently important and the people involved are sufficiently skilled. He Jiankui's reappearance is a stress test for that principle, and the result of that test will be worth watching closely over the next twelve to eighteen months as his lab either produces credible science, attracts visible institutional support, or quietly disappears again.
Also read: Agentic AI is moving from boardroom buzzword to operational reality in 2026 • Unsloth found and fixed a bug in Mistral Medium 3.5 and the story reveals how much of the open-weight model race is actually a tooling race • Viral prompts for fake old photos reveal how synthetic nostalgia is becoming one of AI image generation's most persuasive and least discussed capabilities
